Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience
Christina Matthews(Roswell Park Comprehensive Cancer Center), Maryam B. Lustberg(Yale Cancer Center), Craig Vargo(University of Pisa), Nicole Williams(The Ohio State University), Jessica Dempsey, Bhuvaneswari Ramaswamy(The Ohio State University), Kristen Nymberg(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Raquel E. Reinbolt(The Ohio State University), Junan Li(University of Shanghai for Science and Technology), Sagar Sardesai(The Ohio State University), Michael Berger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robert Wesolowski(The Ohio State University Wexner Medical Center)
Cited by 12
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
|Nature Reviews Clinical Oncology|2023|296
Triple-negative breast cancer: promising prognostic biomarkers currently in development
|Expert Review of Anticancer Therapy|2020|236